MedTrace Logo

Trifecta-Lung cfDNA-MMDx Study

NCT05837663 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-03-05

No results posted yet for this study

Summary

Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.

Conditions

  • Lung Transplantation

Sponsors & Collaborators

  • Natera, Inc.

    collaborator INDUSTRY

  • One Lambda

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Principal Investigators

  • Philip F Halloran, MD PhD · Alberta Transplant Applied Genomics Centre, University of Alberta

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2026-11-30
Completion
2027-12-31

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05837663 on ClinicalTrials.gov